![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 38, 27323-27330, September 17, 1999
-Aminobutyric Acid Type B Receptor Splice Variant Proteins
GBR1a and GBR1b Are Both Associated with GBR2 in Situ and
Display Differential Regional and Subcellular Distribution*
,
From the Institute of Pharmacology, The subunit architecture of Inhibitory neurotransmission is mainly mediated by
Despite the various functions of GABAB receptors, molecular
cloning initially revealed only two receptor subtypes generated by
alternative splicing of a single gene. These variants of the GABAB receptor, termed GBR1a and GBR1b, differ solely in
their N terminus, where the first 147 residues of GBR1a are replaced by
a sequence of 18 different amino acids in GBR1b (3). In situ
hybridization histochemistry (3) and immunohistochemistry (4) with
probes that did not discriminate between the GBR1a and GBR1b variants
suggested that GBR1a and GBR1b represent the vast majority of
GABAB receptors since their widespread distribution resembled that of GABAB receptors detected by
autoradiography using radioligands. However, GBR1a and GBR1b expressed
in COS-1 cells displayed up to 150-fold lower affinity for agonists
compared with native GABAB receptors, and coupling of GBR1
to certain effector systems was difficult to demonstrate (3, 5). An
explanation for this discrepancy was provided by the observation that
GBR1 remained largely trapped in the endoplasmic reticulum when
expressed transiently in mammalian cells (6). Recently, a second
seven-transmembrane domain component of GABAB receptors,
GBR2, was identified, which is similar in size to GBR1 and shares about
35% sequence identity (7-11). Upon co-expression in heterologous
expression systems GBR1 and GBR2 formed heteromers, which were targeted
to the cell surface membrane and displayed robust activation of
G-protein-regulated K+ channels as well as inhibition of
forskolin-induced cAMP production with half-maximal effector
concentrations similar to those observed for native GABAB
receptors (7-11). Thus, unlike other G-protein-coupled receptors,
functional GABAB receptors appear to be heteromers formed
from two related seven-transmembrane domain proteins, GBR1 and GBR2.
However, there is evidence that also GBR1a and GBR1b alone were able to
couple to K+ channels or adenylyl cyclase, although at low
efficiency (3, 12). In addition, GBR2 expressed in HEK 293 cells was
found to inhibit forskolin-stimulated cAMP production in the presence of GABA (8). Thus, GABAB receptors with monomeric or
diverse, yet unknown, heteromeric structures may occur in
vivo. It was therefore tested whether both GBR1a and GBR1b are
associated with GBR2 in situ and whether GBR1a and GBR1b may
be co-assembled to provide further receptor heterogeneity. In addition,
it was analyzed whether the GABAB receptor components
GBR1a, GBR1b, or GBR2 may also be present as monomers in
situ and thereby contribute to further receptor heterogeneity.
Finally, the regional and subcellular distributions of GBR1a, GBR1b,
and GBR2 were analyzed to detect possible differential localizations,
which may point to distinct functions of GABAB receptor
subtypes. For this purpose variant-selective antisera were used to
immunobiochemically characterize the GBR1a and GBR1b subtypes and their
relationship to GBR2. The results indicate that GBR1a and GBR1b
represent distinct GABAB receptor subtypes, which are
targeted to largely different subcellular locations. Both GBR1a and
GBR1b exist as heterodimers in combination with GBR2. There was no
evidence for the presence of a major population of monomeric receptors.
Most remarkably, after solubilization, the two GABAB
receptor variants were both found to exist in two forms differing in
molecular size. Thus, receptor-associated components may contribute
further to the heterogeneity of GABAB receptors.
Generation of Antibodies--
For production of variant-specific
antisera the following peptides were custom-synthesized (ANAWA Trading
SA, Switzerland): N-terminal amino acids 83-107 of the GBR1a variant
(sequence, CSKSYLTLENGKVFLTGGDLPALDG), N-terminal amino acids 1-18 of
the GBR1b variant (sequence, SHSPHLPRPHPRVPPHPS containing an
additional cysteine at the C terminus), and the C-terminal amino acids
922-944 common to both GABAB receptor variants (sequence,
PRGPSEPPDRLSSDGSRVHLLYK, containing an additional cysteine at the N
terminus; a naturally occurring cysteine at position 13 was exchanged
by a serine to allow defined coupling to the carrier protein). The
peptides were coupled via the cysteine residue to keyhole limpet
hemocyanin and used for immunizing rabbits as described previously
(13). All resulting antisera were purified by affinity chromatography using the peptide antigens coupled to thiopropyl-Sepharose 6B as matrix
(13).
For detection of GBR2, affinity purified antiserum AbC22 (GBR2
antiserum) was used, which was raised against a glutathione S-transferase fusion protein corresponding to the amino
acids 806-907 of GBR2 (for details see Ref. 7).
Preparation of Crude Brain Membranes and Subcellular
Fractionation--
Brain tissue from male Harlan Sprague-Dawley rats
(200-250 g) was homogenized in 10 volumes of 5 mM
Tris/HCl, pH 7.4, containing 0.32 M sucrose and centrifuged
for 15 min at 1000 × g. The crude membrane fraction
was obtained by centrifugation of the resulting supernatant for 30 min
at 17,000 × g. The membranes were washed twice with 50 mM Tris/HCl, pH 7.4, resuspended in the same buffer to give
a protein concentration of about 5 mg/ml, and stored at
Subcellular fractionation and isolation of postsynaptic densities (PSD)
were done according to Ref. 14. Cortex and hippocampus of adult rats
were rapidly dissected and homogenized (10% w/v) in 0.32 M
sucrose, 1 mM NaHCO3, 1 mM
MgCl2, 0.5 mM CaCl2 (buffer A) by
12 up and down strokes with a motor-operated Teflon-glass homogenization. The homogenate was centrifuged for 10 min at 1500 × g, and the resulting pellet (P1) was washed once with
buffer A by homogenization and centrifugation for 10 min at 755 × g. The combined supernatants were centrifuged for 10 min at
17,300 × g resulting in the crude membrane preparation
(P2). The pellet was washed once in buffer A, resuspended in 0.32 M sucrose, 1 mM NaHCO3 (buffer B)
and centrifuged for 120 min at 100,000 × g on
discontinuous sucrose gradients (each 9 ml contained 1.2, 1, and 0.85 M sucrose containing 1 mM NaHCO3).
The band between 1.0 and 1.2 M sucrose was removed, diluted
with buffer B, and centrifuged for 20 min at 48,200 × g. The resulting synaptosomal membranes (SPM) were
resuspended in 25 mM Tris, pH 7.3, containing 0.5% Triton
X-100 to a protein concentration of 4 mg/ml, stirred on ice for 15 min,
followed by centrifugation for 20 min at 48,200 × g.
The pellet was resuspended in 50 mM Tris, pH 7.3, and
postsynaptic densities (PSD) were isolated by centrifugation for 120 min at 275,000 × g on a discontinuous sucrose gradient
(each 3 ml contained 2, 1.5, and 1 M sucrose containing 1 mM NaHCO3). The PSD fraction (band between 1.5 and 2 M sucrose) was diluted to 5.5 ml with H2O
followed by addition of an equal volume of 1% Triton X-100, 150 mM KCl, incubated for 60 min on ice and pelleted by
centrifugation for 60 min at 275,000 × g.
Further subcellular fractions were prepared as follows. The supernatant
of the crude membrane preparation (S2) was centrifuged for 60 min at
100,000 × g to obtain microsomal membranes (P3) and
the cytosolic fraction (S3). The synaptosomal fraction (SPM) was
resuspended in 5 mM Tris, pH 7.3, 1 mM EDTA,
0.05% Triton X-100 and subjected to osmotic lysis for 60 min on ice
followed by centrifugation for 20 min at 48,200 × g
resulting in the lysed synaptosomal membranes (LP1) and the cytosolic
synaptosomal fraction (LS1).
Western Blotting--
Aliquots of the crude membranes or
subcellular fractions were incubated for 15 min at 60 °C with an
equal volume of 125 mM Tris/HCl, pH 6.8, 20% glycerol,
0.002% bromphenol blue, 10%
Quantification of immunoreactive bands was performed with a high
resolution computer-based image analysis system (MCID M2, Imaging
Research, Ontario, Canada). To ensure an analysis in the linear ranges,
x-ray films were exposed to Western blots of increasing protein
concentrations (2.5-40 µg) for various times.
Solubilization of GABAB Receptors--
For
solubilization of GABAB receptors, crude membranes were
thawed and washed once with 10 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 200 mg/l bacitracin, 0.1 mM phenylmethylsulfonyl fluoride, 2.3 mg/liter aprotinin, 1 mM benzamidine, 0.05% phosphatidylcholine and resuspended
in the same buffer to give a protein concentration of 5 mg/ml.
Following addition of the detergent (either 1% Triton X-100, 0.5%
sodium deoxycholate, 2% CHAPS, 2% BigCHAP, 2%
octyl- Sucrose Density Gradient Centrifugation--
Linear gradients
were prepared from 5 and 20% sucrose in 50 mM Tris/HCl, pH
8.0, 0.02% NaN3 containing either 0.1% deoxycholate or
0.5% Triton X-100. Deoxycholate extracts of brain membranes (200 µl,
see above) were layered on the top of each gradient and were
centrifuged at 170,000 × g for 14 h at 4 °C.
At the end of the centrifugation, fractions of 300 µl were collected
and analyzed for GBR1 and GBR2 immunoreactivity (IR) by Western
blotting. For calibration, marker proteins (2 mg/ml bovine serum
albumin, aldolase, and catalase, were dissolved in 10 mM
Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 200 mg/liter bacitracin, 0.1 mM phenylmethylsulfonyl fluoride,
2.3 mg/liter aprotinin, 1 mM benzamidine, 0.05%
phosphatidylcholine, 0.5% deoxycholate and applied to gradients run in
parallel. The presence of marker proteins in each fraction was
determined by SDS-PAGE and by measuring the optical density of the
fractions at a wavelength of 280 nm. In addition, the position of
GABAA receptors was determined by Western blotting using
antisera against the Immunoaffinity Chromatography--
For construction of a
GBR1b-specific immunoaffinity column, affinity purified antibodies were
coupled to protein A-agarose as described previously (16). Crude
membranes prepared from whole rat brain were solubilized in 0.5%
deoxycholate as described above and circulated through the columns
overnight at 4 °C. The columns were extensively washed with 50 mM Tris/HCl, pH 8.0, 150 mM NaCl, 1 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride,
0.1% deoxycholate, 0.02% NaN3 followed by 5 mM Tris/HCl, pH 8.0, 0.1% deoxycholate. Bound receptors
were eluted with 0.1 M Na2HPO4, pH
11.5, 0.5 M urea, 0.1% deoxycholate, immediately
neutralized with 1 M NaH2PO4,
concentrated by ultrafiltration (Centricon 30 concentrators, Amicon
Inc.), and subjected to Western blot analysis.
Histoblotting--
The regional distribution of the GBR1a,
GBR1b, and GBR2 proteins in the adult rat brain was analyzed using the
histoblot technique as described previously (17-19). Parasagittal
cryostat-cut sections (16 µm) of rat brains were collected onto
nitrocellulose membranes (0.45 µm, Bio-Rad) and kept frozen at
Cell Culture and Transfection--
Human embryonic kidney cells
(ATCC CRL 1573, 293 cells) were grown on culture dishes (9 cm) in
minimal essential medium (Life Technologies, Inc.) supplemented with
8% heat-inactivated fetal calf serum and 10 µg/ml gentamycin. Cells
were transfected with 30 µg of GBR1a or GBR1b variant expression
plasmids using the calcium phosphate precipitation technique. For
harvesting, culture dishes were washed with ice-cold buffer (10 mM Tris/HCl, pH 7.4, 0.32 M sucrose, 5 mM EDTA, 0.1 mM phenylmethylsulfonyl fluoride) followed by scraping the cells in buffer and centrifugation at 3,000 × g for 10 min. The cell pellets were stored at
Generation and Characterization of Splice Variant-selective
Antisera--
Affinity purified polyclonal antisera directed against
the GABAB receptor splice variants GBR1a and GBR1b were
generated using synthetic peptides derived from the N-terminal domain,
which differs between the two splice variants (GBR1a-(83-107) and
GBR1b-(1-18)). In addition, an antiserum was raised against the C
terminus common to both splice variants (GBR1a,b-(922-944)). On
Western blots of crude rat brain membranes, the GBR1a-(83-107)
antiserum detected a broad protein band of 130 kDa, the GBR1b-(1-18)
antiserum a broad protein band of 100 kDa, and the GBR1a,b-(922-944)
antiserum correspondingly two proteins of 100 and 130 kDa, respectively (Fig. 1A). The
immunoreactivities (IR) were completely prevented by co-incubation of
the antisera with the corresponding peptide antigens underscoring the
specificity of the antisera (Fig. 1A). Since the
GBR1a-(83-107) and GBR1b-(1-18) antisera recognized proteins of
distinct sizes, a cross-reactivity of the antisera was not expected. To
assess further the variant selectivity of the antisera, human embryonic
kidney (HEK 293) cells were transfected with the GBR1a or GBR1b clone
and analyzed by Western blotting for the presence of the respective
variants. In HEK 293 cells expressing the GBR1a variant, a 130-kDa
protein was stained by the GBR1a-(83-107) and GBR1a,b-(922-944)
antisera, whereas no IR was found with the GBR1b-(1-18) antiserum
(Fig. 1B). Conversely, in HEK 293 cells expressing the GBR1b
variant, a 100-kDa protein was detected with the GBR1b-(1-18) and
GBR1a,b-(922-944) antisera, but no IR was observed with the
GBR1a-(83-107) antiserum (Fig. 1B). In controls with
non-transfected cells none of the antisera showed an IR. Thus, the
GBR1a-(83-107) and GBR1b-(1-18) antisera were specific for the
GABAB receptors' splice variants GBR1a and GBR1b and
lacked any cross-reactivity. The selectivity of the GBR2 antiserum was
described previously (7).
Native GABAB Receptor Subtypes Are
Heterodimers--
Recent studies on mainly recombinant receptors
indicated that fully functional GABAB receptors are
heterodimers assembled from GBR1 and GBR2 (7-10). To test whether an
association of GBR1 with GBR2 also holds for the native
GABAB receptor variants, immunopurification experiments
were performed. As a prerequisite, optimal solubilization conditions
were determined. Crude brain membranes were treated with different
detergents followed by Western blot analysis of both the extract and
insoluble material using the GBR1a,b-(922-944) antiserum. Among the
detergents tested, the ionic detergent deoxycholate (0.5%) and the
detergent mixture RIPA (0.5% sodium deoxycholate, 1% Nonidet P-40,
0.1% SDS) solubilized both GABAB receptor variants most
efficiently (Fig. 2). All non-ionic and
zwitterionic detergents tested (1% Triton X-100, 2% CHAPS, 2%
BigCHAP, and 2% octyl-
The ability of GBR1a and GBR1b to associate with GBR2 was analyzed by
immunoprecipitating GABAB receptors from deoxycholate extracts of brain membranes using the GBR2 antiserum. In the well washed immunoprecipitate an IR for both GBR1a and GBR1b was detected on
Western blots with the GBR1a,b-(922-944) antiserum, demonstrating that
both GBR1a and GBR1b are associated with GBR2 in native
GABAB receptors (Fig.
3A). In addition, the possible
presence of trimeric receptors made up of GBR1a, GBR1b, and GBR2
was investigated. For this purpose, immunoaffinity chromatography of
deoxycholate extracts of brain membranes was performed using GBR1b
antibodies coupled to protein A-agarose. GBR1b antibodies were chosen
for construction of the immunoaffinity column since GBR1a antibodies lost their activity upon coupling to protein A-agarose. Following extensive washing of the column, bound proteins were eluted with 0.1 M Na2HPO4, pH 11.5, and analyzed by
Western blotting. On Western blots of receptors immunoisolated with
GBR1b antibodies, only signals for GBR1b and GBR2 were observed but not
for GBR1a (Fig. 3B). Consequently, GBR1a and GBR1b do not
appear to co-assemble to a measurable extent in situ. Thus,
native GBR1a and GBR1b represent distinct receptor subtypes, which are
both associated with GBR2 to form heteromers in situ.
Native GABAB Receptor Variants Each Occur in Two
Molecular Forms--
To assess whether the constituent proteins of
GABAB receptors, in addition to forming heteromers, may
also occur as monomers or homo-oligomers, the molecular size of native
solubilized receptors was analyzed by sucrose density gradient
centrifugation. Proteins of rat brain membranes were extracted with
0.5% deoxycholate and subjected to 5-20% linear sucrose density
gradient centrifugation, followed by an analysis of the pattern of
distribution of GBR1a and GBR1b and GBR2. Western blotting revealed IR
for GBR1a, GBR1b, and GBR2 in the same fractions, pointing to their
co-sedimentation. The relative staining intensity of GBR2 roughly
corresponded to that of GB1a and GB1b IR, in line with the association
of GBR1 and GBR2 (Fig. 4). Surprisingly,
the two GBR1 proteins and the GBR2 protein were present in two distinct
peaks. The first broad peak, containing the majority of GBR1a, GBR1b,
and GBR2 proteins, migrated to a position between that of the marker
proteins aldolase (158 kDa) and catalase (232 kDa) and overlapped with
GABAA receptors as marker protein (~250 kDa). The second
receptor fraction migrated slightly further into the gradient than the
GABAA receptor marker, suggesting a molecular size of >250
kDa. The two molecular forms of GABAB receptors were found
irrespective of the detergent used. Solubilization of GABAB
receptors with Triton X-100 (1%) or CHAPS (2%) and inclusion of the
respective detergent in the sucrose density gradients resulted likewise
in the high and low molecular forms (not shown). Both molecular forms
of GABAB receptors were also detected by size-exclusion
chromatography on a Superose 6HR 10/30 column using a fast liquid
chromatography system (Amersham Pharmacia Biotech) (not shown). Most
importantly, since GABAB receptor IR was not eluted in the
void volume of the column, it is unlikely that GABAB
receptors strongly aggregate nonspecifically under the conditions used.
The high molecular form of GABAB receptors is therefore not
expected to represent aggregated receptor protein.
To demonstrate directly the association of GBR1 with GBR2 in both
GABAB receptor peaks, GABAB receptors were
immunoprecipitated from individual fractions taken from the high and
low molecular weight forms (Fig. 4B). Immunoprecipitation
was performed with the GBR1a,b-(922-944) antiserum, and the
precipitate was tested for the presence of GBR1a, GBR1b, and GBR2 by
Western blotting. In both, the high and low molecular size fractions
GBR1a and GBR1b were co-precipitated with GBR2 (Fig.
4B).
Since in all fractions tested GBR1a and GBR1b were found to be
associated with GBR2, it is unlikely that considerable amounts of
monomeric GABAB receptors are present in brain. However, to rule out the existence of monomeric GABAB receptors,
quantitative immunoprecipitation experiments were performed.
GABAB receptor proteins GBR1a, GBR1b, or GBR2 were
immunoprecipitated from deoxycholate extracts of brain membranes with
the GBR1a,b-(922-944) or GBR2 antiserum, respectively. Following
precipitation of the receptor-antibody complex with protein A-agarose
the immunoprecipitation was repeated two times with the resulting
supernatants to ensure quantitative depletion of either GBR1a and GBR1b
or GBR2 by the respective antiserum. Western blot analysis revealed
that neither in the GBR1a- and GBR1b-depleted supernatant nor in the
GBR2-depleted extract either GBR2 or GBR1a/GBR1b were detectable (Fig.
5). This result indicated that no
measurable population of monomeric or homo-oligomeric GBR1a, GBR1b, or
GBR2 were present in the brain extracts.
Since GBR1a and GBR1b do not appear to heteromize (Fig. 3), the high
molecular weight form of GABAB receptors (>250 kDa)
identified in the sucrose density gradients is unlikely be due to the
existence of multimeric complexes built up of GBR1a, GBR1b, and GBR2.
It was therefore tested whether the differences in size of
GABAB receptors is due to the formation of disulfide
bridges, as demonstrated for metabotropic glutamate receptors (20).
However, on Western blots performed under non-reducing conditions GBR1
and GBR2 proteins migrate as monomers, arguing against a dimerization
via disulfide bridges. Likewise, inclusion of dithiothreitol (10 mM) into the sucrose density gradients did not affect the
migration of GBR1a, GBR1b, or GBR2 (not shown). Thus, the high
molecular weight forms may either be due to variations in the
stoichiometry of the receptor subunits or due to the association of at
least some GABAB receptors with yet unknown proteins.
Differential Regional Distribution of GBR1a and GBR1b--
On
Western blots of whole brain membranes staining of the GBR1a variant
was consistently weaker than that of the GBR1b variant when the
GBR1a,b-(922-944) antiserum was used (Figs. 1 and 2). Since the
GBR1a,b-(922-944) antiserum was raised against a peptide sequence that
is identical in GBR1a and GBR1b proteins, the GBR1a,b-(922-944) antiserum permitted a direct comparison of the relative abundance of
the GBR1a and GBR1b variants in brain tissue. Densitometric analysis of
Western blots with increasing protein concentrations of membranes
prepared from whole rat brains revealed that GBR1b is 2.1 ± 0.5 (n = 6)-fold more abundant than GBR1a (Fig.
6). Thus, the two GABAB
receptor subtypes were expected to display a different distribution on
the regional and cellular level in the brain. The regional distribution
of GBR1a, GBR1b, and GBR2 proteins was analyzed by Western blotting
using membranes prepared from seven major brain regions. All three
GABAB receptor proteins displayed a widespread
distribution, being present in all brain areas analyzed with the
highest relative expression in the cerebral cortex and cerebellum (Fig.
7A). However, the presence of
the GBR1 splice variants differed considerably among brain regions.
Whereas GBR1a and GBR1b were expressed to a similar extent in the
hippocampus, GBR1a predominated in the olfactory bulb and striatum, and
GBR1b was more abundant than GBR1a in cerebral cortex, thalamus,
cerebellum, and medulla. The staining intensity for GBR2, which
appeared to correspond to the sum of GBR1a and GBR1b-IR in the
different brain areas, was strongest in cerebral cortex, hippocampal
formation, thalamus, and cerebellum, followed by the olfactory bulb,
striatum, and medulla (Fig. 7A).
The distribution of GBR1a, GBR1b, and GBR2 was analyzed in more detail
in sections of adult rat brain. Since the GBR1a-(83-107) antiserum
failed to recognize the GBR1a protein in perfusion-fixed brain tissue
processed for immunohistochemistry, the histoblot technique was used
(17-19). Parasagittal cryostat-cut sections were blotted onto
nitrocellulose membranes, providing a protein image of the section for
immunostaining performed according to the protocol of Western blotting
(Fig. 7B). The histoblot technique offered very high
sensitivity and high signal to noise ratios, making it the method of
choice for an analysis of the gross regional distribution of GBR
proteins, although lacking cellular resolution. GBR1a-IR was observed
throughout the brain with higher than average levels in the external
plexiform layer of the olfactory bulb, CA1 region of the hippocampus,
superior colliculus, and striatum. GBR1b was distributed as widespread
as GBR1a but displayed much larger regional differences in staining
intensity. Strongest GBR1b-IR was seen in the thalamus, outer layers of
the cerebral cortex, and molecular layer of the cerebellum, whereas
moderate staining was observed in the hippocampus and amygdala, and
faint staining was observed in the olfactory bulb, striatum, basal
ganglia, mesencephalon, pons, and medulla. Interestingly, the sum of
GBR1a and GBR1b patterns of distribution and staining intensities, as
visualized with the GBR1a,b-(922-944) antiserum, strikingly matched
that of GBR2 (Fig. 7B), supporting the view that GBR1a and
GBR1b are both associated with GBR2 in all brain areas to form
functional GABAB receptors.
Differential Subcellular Distribution of GBR1a and GBR1b
Variants--
In order to analyze the subcellular distribution of
GBR1a, GBR1b, and GBR2 proteins, homogenates of rat brain were
fractionated by differential centrifugation. Western blot analysis of
the various cellular subfractions demonstrated a distribution of GBR1a,
GBR1b, and GBR2 proteins consistent with a synaptic membrane
localization. All three proteins were enriched in fractions containing
synaptic plasma membranes, i.e. synaptic plasma membranes
(SPM) and lysed synaptic plasma membranes (LP-SPM) (Fig.
8). A potential postsynaptic localization
of the GABAB receptor proteins GBR1a, GBR1b, and GBR2 was
investigated by purifying PSD. PSDs are specializations of the
cytoskeleton, located beneath the postsynaptic membrane, which forms a
disc that consists of cytoskeletal and regulatory proteins, partially
involved in the anchoring of neurotransmitter receptors (reviewed in
Ref. 21). In highly purified PSDs (14) a striking difference in the
enrichment of GBR1a and GBR1b variants was apparent. Whereas strong
GBR1a-IR was detected in the PSD fraction, only faint signals were
observed for the GBR1b variant (Fig. 8), suggesting that the GBR1a and
GBR1b variants differ in their extent of postsynaptic localization. In
addition, GBR1-IR and GBR2-IR was detected in fractions containing
membranes of the endoplasmic reticulum and the Golgi apparatus (P3 and
LS-SPM), pointing to the existence of an intracellular pool of
GABAB receptors in neurons (Fig. 8).
For GABAB receptors, two constituent proteins with a
seven-transmembrane domain topology, GBR1 and GBR2, are known, of which GBR1 exists in two splice variants (3, 7-11). In situ, the subunit composition of the two GABAB receptor variants is
yet unknown. In the present study, the structural organization as well
as the regional and subcellular distribution of the two
GABAB receptor subtypes were analyzed in rat brain with
antibodies selectively recognizing the GBR1a, GBR1b, or GBR2 proteins.
The results suggest that GBR1a and GBR1b characterize two distinct
receptor populations, which both contain GBR2. There was no indication
for the presence of monomeric or homo-oligomeric GABAB
receptor components. Most interestingly, determination of the size of
native GABAB receptors pointed to the presence of yet
unknown receptor associated proteins. Striking differences in the
relative abundance of GBR1a and GBR1b as well as their regional and
subcellular distribution suggest that they differ in their targeting
specificity and may thus serve distinct functions in neuronal signaling.
Heteromerization of GBR1a and GBR1b with GBR2 in Rat Brain--
To
date, the only examples for a heterodimerization of G-protein-coupled
receptors are opioid receptors, which are able to form functional
recombinant
Although their solubilization by deoxycholate was not quantitative
(GBR1a, 58 ± 5%; GBR1b, 56 ± 5%), GBR1a and GBR1b were extracted to an equal extent (Fig. 2), ensuring comparable receptor concentrations in the supernatant. When solubilized GABAB
receptors were immunopurified using GBR1b-(1-18) or GBR2 antibodies,
both GBR1a and GBR1b were found to be associated with GBR2 (Figs. 3 and
4). Moreover, the results did not support the presence of GABAB receptors in which the two splice variants GBR1a and
GBR1b were co-assembled (Fig. 3B). This result is further
supported by the observation that the C termini of GBR1 and GBR2 do not form homo-oligomers in the yeast two-hybrid system (8, 10). Thus, the
brain appears to largely contain two distinct receptor subtypes with
the subunit combination GBR1a/GBR2 and GBR1b/GBR2. An association of
GBR1a or GBR1b with GBR2 in native GABAB receptors is
further substantiated by their overlapping pattern of distribution and
relative abundance as detected by the histoblot technique on brain
slices on a regional level (Fig. 7). The degree of GBR2 IR largely
corresponded to the sum of GB1a and GBR1b IR.
Homomeric GABAB receptors have been suggested to be
functional as tested in heterologous expression systems. This was based on the observation that GBR2 expressed in HEK 293 cells induced a
decrease in forskolin-stimulated cAMP production to the same extent as
that detected after co-expression of GBR1 with GBR2 (8). In addition,
the coupling of GBR1 to adenylyl cyclase and K+ channels
has been detected (3, 12). However, molecular size estimation of
solubilized GABAB receptors using sucrose density gradient
centrifugation did not reveal an indication for the presence of
monomers for GBR1a, GBR1b, or GBR2 as detected by Western blotting. Moreover, quantitative immunoprecipitation of solubilized receptors with the GBR2 or the GBR1a,b-(922-944) antiserum resulted in the precipitation of the entire population of GABAB receptors;
the supernatants did not contain any measurable amounts of excess GBR1a, GBR1b, or GBR2. Thus, there was no evidence for the presence of
monomeric or homo-oligomeric forms of GABAB receptors in
brain (Fig. 5).
Most interestingly, the molecular size estimation of native solubilized
GABAB receptors by sucrose density gradient centrifugation revealed two different molecular forms. The lower molecular weight peak, which contained the majority of GABAB receptors, can
be attributed to heterodimeric receptors GBR1a/GBR2 and GBR1b/GBR2. The
receptor populations with the higher molecular size, which likewise
contained GBR1a and GBR1b in association with GBR2, are unlikely to
consist of heterotrimeric GBR1a/GBR1b/GBR2 receptors since
GBR1b-specific immunoaffinity chromatography ruled out an association
of GBR1b with GBR1a (Fig. 3). Furthermore, the high molecular weight
GABAB receptors are not due to a dimerization via disulfide
bridges, as in the case of metabotropic glutamate receptors, which, in
contrast to GABAB receptors, contain four highly conserved
cysteine residues in the N-terminal domain (20). Although metabotropic
glutamate receptors migrate as dimers under non-reducing conditions
(20), GBR1a, GBR1b, and GBR2 migrate as monomers. Thus, the high
molecular forms of GBR1a/GBR2 and GBR1b/GBR2 may rather represent
complexes with yet unidentified proteins, possibly involved in the
regulation or anchoring of GABAB receptors. The coiled-coil
domains in the C termini of GBR1 and GBR2 (8, 10) may be preferred
sites of interaction with accessory proteins (22) in addition to the
putative PDZ-interacting module at the GBR1 and the GBR2 C terminus
(5).
Differential Regional Distribution and Subcellular Targeting of
GBR1a and GBR1b--
In line with previous immunohistochemical
evidence using the GBR1b-(1-18) and GBR1a,b-(922-944) antisera (4),
the pattern and the sum of the staining intensities of GBR1a and GBR1b
matched the distribution and staining intensity of GBR2 (Fig. 7).
Furthermore, the regional pattern of the GABAB receptor
proteins GBR1a, GBR1b, and GBR2 also corresponded to that of the
respective mRNAs analyzed by in situ hybridization
histochemistry (7-9). Finally, the distribution of GABAB
receptor-binding sites detected autoradiographically (23-25)
corresponded to the pattern of GABAB receptor proteins. Thus, the vast majority of GABAB receptors appear to
consist of two isoforms with the subunit combinations GBR1a/GBR2 and
GBR1b/GBR2. However, since GBR1a and GBR1b variants represent distinct
GABAB receptor subtypes, they were expected to differ in
their regional distribution. In general, the GB1b variant was more
abundant than the GBR1a variant, although the latter predominated in
some brain areas (e.g. olfactory bulb, striatum, and CAI
region of the hippocampus; Fig. 7).
In some brain areas (olfactory bulb, striatum, and hypothalamus), the
relative signal intensity of GBR2 mRNA in in situ
hybridization histochemistry was considerably lower than that of GBR1
mRNA (7-9). This finding led to the suggestion that not all GBR1
proteins may be associated with GBR2. However, on the protein level,
the ratio of GBR1 to GBR2 was not different from that in other brain areas (Fig. 7). The discrepancy between the mRNA and protein ratios suggests that GABAB receptors may be subject to regionally
different transcriptional and/or post-transcriptional regulation. It
will therefore be of interest to determine whether GABAB
receptors are subject to regionally distinctive translational control.
Presynaptic GABAB receptors have been reported to be
pharmacologically distinct from those of postsynaptic receptors in
several brain areas (26-29). It has been speculated that GBR1a and
GBR1b might be the structural correlates for post- and presynaptic
receptors, respectively (3). Indeed, GBR1a appears to be preferentially located postsynaptically as shown by their prevalence in purified PSDs.
Conversely, GBR1b IR, which was only rarely present in the PSD fraction
(Fig. 8), may be preferentially localized at pre- and extrasynaptic
sites. A differential localization of GBR1a and GBR1b may be mediated
via the distinctive extracellular N-terminal domain, e.g. by
the sushi repeats for extracellular protein contacts present
exclusively on GBR1a (5).
In conclusion, the results indicate that the vast majority of
GABAB receptors are represented by two populations of
heterodimeric receptors GBR1a/GBR2 and GBR1b/GBR2. These two distinct
receptor subtypes are localized to mainly distinct subcellular sites,
with GBR1b being rarely located in postsynaptic densities. There was no
indication for the presence of monomers of GBR1a, GBR1b, or GBR2 in the
brain or a trimeric population of receptors containing GBR1a/GBR1b/GBR2.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The abbreviations used are:
GABA,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-aminobutyric
acid, type B (GABAB), receptors in situ
is largely unknown. The GABAB receptor variants,
characterized by the constituents GBR1a and GBR1b, were therefore
analyzed with regard to their subunit composition as well as their
regional and subcellular distribution in situ. The analysis
was based on the use of antisera recognizing selectively GBR1a, GBR1b,
and GBR2. Following their solubilization, GBR1a and GBR1b were both
found by immunoprecipitation to occur as heterodimers associated with
GBR2. Furthermore, monomers of GBR1a, GBR1b, or GBR2 were not
detectable, suggesting that practically all GABAB receptors
are heterodimers in situ. Finally, there was no evidence for an association of GBR1a with GBR1b indicating that these two constituents represent two different receptor populations. A size determination of solubilized GABAB receptors by sucrose
density centrifugation revealed two distinct peaks of which one
corresponded to dimeric receptors, and the higher molecular weight peak
pointed to the presence of yet unknown receptor-associated proteins.
The distribution and relative abundance of GBR2 immunoreactivity
corresponded in all brain regions to that of the sum of GBR1a and
GBR1b, supporting the view that most if not all GBR1 proteins are
associated with GBR2. However, GBR1a was present preferentially at
postsynaptic densities, whereas GBR1b may be mainly attributed to
presynaptic or extrasynaptic sites. Thus, GBR1a and GBR1b are both
associated with GBR2 to form heterodimers at mainly different
subcellular locations where they are expected to subserve different functions.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-aminobutyric acid (GABA)1
that displays a fast and a slow component. Whereas the fast inhibitory response results from the activation of the postsynaptically localized GABAA receptors by triggering the opening of an integral
Cl
channel, the slow GABA action is mediated by the
metabotropic GABAB receptors. GABAB receptors
can be localized pre- and postsynaptically, where they interact via
G-proteins with a variety of effector systems (reviewed in Refs. 1 and
2). Postsynaptic GABAB receptors activate K+
channels and regulate adenylyl cyclase. Presynaptic GABAB
receptors inhibit the release of neurotransmitters by modulation of
Ca2+ channels.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
30 °C.
-mercaptoethanol, 4% SDS and
subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) using 7.5% mini-gels (Mini Protean II, Bio-Rad). Proteins
were transferred onto polyvinylidene difluoride or nitrocellulose
membranes in a semi-dry electro-blotting apparatus (Trans-Blot,
Bio-Rad) at 15 V for 60 min using 39 mM glycine, 48 mM Tris, 0.04% SDS as transfer buffer. For
immunodetection, the blots were blocked for 1-2 h in TBST (10 mM Tris/HCl, pH 8, 0.15 M NaCl, 0.05% Tween
20) containing 5% non-fat dry milk (=blocker) at room temperature,
followed by incubation with affinity purified antisera overnight at
4 °C in TBST, 5% blocker. The blots were washed one time for 10 min
with 20 mM Tris, pH 7.5, 60 mM NaCl, 2 mM EDTA, 0.4% SDS, 0.4% Triton X-100, 0.4% deoxycholate
and three times with TBST. Incubation with secondary antibodies
(horseradish peroxidase-conjugated goat anti-rabbit IgG diluted 1:5000
in TBST, 5% blocker; Promega) was carried out for 1 h at room
temperature. Following extensive washing (see above), immunoreactivity
was detected by the chemiluminescence method (Western Blot
Chemiluminescence Reagent Plus; NEN Life Science Products).
-D-glucopyranoside or RIPA (0.5% sodium
deoxycholate), 1% Nonidet P-40, 0.1% SDS; final concentrations), the
mixture was incubated for 30 min on ice, and insoluble material was
removed by centrifugation for 60 min at 100,000 × g.
The supernatant was carefully removed, and the remaining pellet was
resuspended in buffer to the original volume. To test the
solubilization efficiency, equal aliquots of the supernatant and pellet
were subjected to Western blotting.
1- and
3-subunits (15).
30 °C until use. For protein transfer, the frozen nitrocellulose
sheets containing the brain sections were moistened with 39 mM glycine, 48 mM Tris, 20% methanol, 2% SDS
and incubated for 5 min at room temperature. After 2 h of
incubation in TBST, 5% blocker, the blots were washed with TBST and
incubated overnight with gentle agitation in 0.1 M Tris, pH
6.8, 2% SDS, 0.1 M
-mercaptoethanol at room temperature
to remove the brain tissue and denature the proteins bound to the nitrocellulose membranes. Following washing with TBST, histoblots were
processed for immunostaining with the GBR1a-, GBR1b-, GBR1a/b-, and
GBR2-selective antisera as described for Western blotting.
80 °C until used. For Western blotting, the cells were thawed,
resuspended in 50 mM Tris/HCl, pH 7.4, 150 mM
KCl, homogenized, and washed twice with buffer.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (23K):
[in a new window]
Fig. 1.
Immunochemical identification of the GBR1a
and GBR1b variants. A, proteins from crude rat brain
membranes (40 µg/lane) were subjected to SDS-PAGE and Western
blotting with affinity purified GBR1a-(83-107) (0.7 µg/ml), GBR1a,
b-(922-944) (0.2 µg/ml), or GBR1b-(1-18) antiserum (0.1 µg/ml) in
the absence or presence of 10 µg/ml of the respective peptide antigen
(+P). B, Western blot analysis of HEK 293 cells
expressing the GBR1a or GBR1b variant. Membranes from HEK 293 cells
expressing either the GBR1a or GBR1b variant were subjected to SDS-PAGE
and Western blotting using the GBR1a-(83-107), GBR1b-(1-18) or
GBR1a,b-(922-944) antiserum.
-D-glucopyranoside) were
considerably less effective in solubilization (Fig. 2). There was no
apparent difference in the efficiency of extracting GBR1a compared with
GBR1b. Thus, deoxycholate was the detergent of choice for
solubilization of both GABAB receptor variants. Increasing the deoxycholate concentration to 1.5% and the ionic strength to 1 M NaCl did not improve the solubilization efficiency (not shown). Quantification of the amount of solubilized GABAB
receptor protein by densitometric analysis of Western blots revealed
that 58 ± 5% (n = 6) of the GBR1a variant and
56 ± 5% (n = 6) of the GBR1b variant were
solubilized by 0.5% deoxycholate.

View larger version (26K):
[in a new window]
Fig. 2.
Solubilization of GABAB
receptors. Crude rat brain membranes (5 mg/ml) were incubated for
30 min on ice with either 1% Triton X-100, 0.5% deoxycholate, RIPA
(0.5% sodium deoxycholate (DOC), 1% Nonidet P-40, 0.1%
SDS), 2% CHAPS, 2% Big-CHAP, or 2%
octyl-
-D-glucopyranoside (OGP) followed by
centrifugation at 100,000 × g. The supernatant was
carefully removed, and the remaining pellet was resuspended in buffer
to the original volume. Equal aliquots of the supernatant
(S) and pellet (P) were subjected to Western
blotting using the GBR1a,b-(922-944) antiserum to test for the
solubilization efficiency. Control refers to membranes treated with
buffer instead of detergent.

View larger version (32K):
[in a new window]
Fig. 3.
Constituents of GABAB receptors
identified by immunoprecipitation and immunoaffinity purification.
A, GABAB receptors were immunoprecipitated from
deoxycholate extracts of whole rat brain membranes with the GBR2
antiserum followed by Western blot analysis using GBR1a,b-(922-944)
and GBR2 antiserum. IR of GBR1a, GBR1b, and GBR2 is indicated by 1a,
1b, and 2, respectively. B, deoxycholate extracts of whole
rat brain membranes were applied to a column containing the
GBR1b-(1-18) antibodies coupled to protein A-Sepharose. After washing,
the eluates were analyzed for the presence of GBR1a, GBR1b, and GBR2
proteins by Western blotting using the GBR1a-(83-107),
GBR1a,b-(922-944), GBR1b-(1-18), and GBR2 antiserum. +P
indicates co-incubation of the antiserum with 10 µg/ml of the
respective peptide antigen. A weak nonspecifically labeled protein band
at about 170 kDa was occasionally observed.

View larger version (40K):
[in a new window]
Fig. 4.
Sucrose density gradient centrifugation of
native GABAB receptors. Deoxycholate extracts of rat
brain membranes (200 µl) were layered on 5-20% linear sucrose
density gradients and centrifuged at 170,000 × g for
14 h at 4 °C. A, after fractionation, individual
fractions were analyzed for GBR1a and GBR1b IR by Western blotting
using the GBR1a,b-(922-944) antiserum. For comparison, the migration
of GABAA receptors (~250 kDa) was probed with a
3-subunit-specific antiserum. The position of marker proteins
(bovine serum albumin, aldolase, and catalase) is indicated on the
top. B, the association of GBR1 with GBR2
proteins in the high and low molecular weight peak of GBR1 and GBR2 IR
observed in the sucrose density gradients was analyzed in
immunoprecipitation experiments. After fractionation, individual
fractions were analyzed for GBR2 IR by Western blotting followed by
immunoprecipitation of GABAB receptors from fractions
displaying strong IR (fractions 6-7 and 13-16) using the
GBR1a,b-(922-944) antiserum. The resulting immunoprecipitates were
analyzed by Western blotting with the GBR1a,b-(922-944) and the GBR2
antiserum.

View larger version (28K):
[in a new window]
Fig. 5.
Quantitative immunoprecipitation of
GBR1a/GBR1b and GBR2 indicates the lack of monomeric and
homo-oligomeric GABAB receptors in rat brain. Crude
membranes prepared from whole rat brains (5 mg of protein/ml) were
solubilized with 0.5% deoxycholate (final concentration) and
centrifuged for 60 min at 100,000 × g, and aliquots of
the resulting supernatant were subjected to immunoprecipitation with
the GBR1a,b-(922-944) and the GBR2 antiserum. Antigen-antibody
complexes were precipitated with protein A-agarose, and the
immunoprecipitation was repeated two times with the resulting
supernatants using the respective antiserum to ensure quantitative
depletion of GBR1a/GBR1b or GBR2. Aliquots of the supernatant after the
third cycle of immunoprecipitation and aliquots of the precipitates
after the first (A), second (B), and third
(C) cycle of immunoprecipitation were analyzed by Western
blotting with the GBR1a,b-(922-944) and the GBR2 antiserum.
C, controls run in parallel in which the antiserum was
replaced by buffer; lane 1, immunoprecipitation with the
GBR1a,b-(922-944) antiserum; lane 2, immunoprecipitation
with the GBR2 antiserum.

View larger version (26K):
[in a new window]
Fig. 6.
Relative abundance of the GBR1a and GBR1b
variants. Crude rat brain membranes containing increasing protein
concentrations (2.5-40 µg) were subjected to Western blotting using
the GBR1a,b-(922-944) antiserum (top). Quantification of
immunoreactive bands was performed with a high resolution
computer-based image analysis system (MCID M2, Imaging Research,
Ontario, Canada). The densitometric analysis of the Western blots
revealed that the GBR1b variant is 2.1 ± 0.5 (n = 6)-fold more abundant than the GBR1a variant.

View larger version (88K):
[in a new window]
Fig. 7.
Regional distribution of GBR1a, GBR1b, and
GBR2 proteins in adult rat brain. A, equal amounts of
crude membranes (40 µg of protein/lane) prepared from olfactory bulb
(Olf. bulb), striatum, cerebral cortex, hippocampus,
thalamus, cerebellum, and medulla/pons were analyzed for
GBR1a-(83-107), GBR1a,b-(922-944), GBR1a,b-(922-944), and GBR2
immunoreactivity by Western blotting. B, GBR1a, GBR1b,
GBR1a/b, and GBR2-IR were visualized in parasagittal rat brain sections
(16 µm) blotted onto nitrocellulose membranes followed by
immunostaining with the GBR1a-(83-107), GBR1a,b-(922-944),
GBR1a,b-(922-944), or GBR2 antiserum. Co-incubation with the
respective peptide antigens (10 µg/ml) completely prevented
immunostaining, underlining its specificity (not shown).

View larger version (53K):
[in a new window]
Fig. 8.
Subcellular distribution of GBR1a, GBR1b, and
GBR2 proteins. Rat brain tissue was subjected to subcellular
fractionation (for details see "Experimental Procedures"), and
aliquots (30 µg) of each fraction were analyzed by Western blotting
using the GBR1a-(83-107), GBR1b-(1-18), GBR1a,b-(922-944), and GBR2
antiserum. H, homogenate; P1, nuclear pellet;
P2, crude membranes; SPM, synaptic plasma
membranes; LP-SPM, lysed synaptosomal membranes;
LS-SPM, cytosolic synaptosomal fractions (also contains
synaptic vesicles and membranes of the endoplasmic reticulum and Golgi
apparatus); P3, light membrane pellet (contains synaptic
vesicles and membranes of the endoplasmic reticulum and Golgi
apparatus); S3, cytosolic fraction (devoid of membranes);
PSD, postsynaptic densities.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
/
dimers (30), and GABAB receptors. Recombinant GABAB receptors are unique among
seven-transmembrane domain receptors, as their targeting to the cell
membrane and their efficient coupling to effector systems largely
require the co-expression of the two constituent proteins GBR1 and GBR2
(7-11). In cerebral cortex both GBR1a and GBR1b were found to be
associated with GBR2 as shown by immunoprecipitation of
125I-CGP 71872 photoaffinity labeled GABAB
receptors (7). However, it was not clear whether GBR1a and GBR1b
assemble with GBR2 in separate receptor subtypes or whether
GABAB receptors consists of ternary complexes containing
both GBR1a and GBR1b together with GBR2. Thus, variant-specific
antisera were required for a detailed investigation of the molecular
organization of native GABAB receptor subtypes.
![]()
FOOTNOTES
To whom correspondence should be addressed: Institute of
Pharmacology, ETH and University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland. Tel.: 41-1-635 59 30; Fax: 41-1-635 68 74;
E-mail: benke@pharma.unizh.ch.
![]()
ABBREVIATIONS
-aminobutyric acid;
GABAA,
-aminobutyric acid, type
A;
GABAB,
-aminobutyric acid, type B;
PSD, postsynaptic
densities;
PAGE, polyacrylamide gel electrophoresis;
IR, immunoreactivity;
SPM, synaptosomal membranes.
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Bowery, N. G.
(1993)
Annu. Rev. Pharmacol. Toxicol.
33,
109-147[Medline]
[Order article via Infotrieve]
2.
Misgeld, U.,
Bijak, M.,
and Jarolimek, W.
(1995)
Prog. Neurobiol.
46,
423-462[CrossRef][Medline]
[Order article via Infotrieve]
3.
Kaupmann, K.,
Huggel, K.,
Heid, J.,
Flor, P. J.,
Bischoff, S.,
Mickel, S. J.,
McMaster, G.,
Angst, C.,
Bittiger, H.,
Froestl, W.,
and Bettler, B.
(1997)
Nature
386,
239-246[CrossRef][Medline]
[Order article via Infotrieve]
4.
Fritschy, J.-M.,
Meskenaite, V.,
Honer, M.,
Benke, D.,
and Mohler, H.
(1999)
Eur. J. Neurosci.
11,
761-768[CrossRef][Medline]
[Order article via Infotrieve]
5.
Bettler, B.,
Kaupmann, K.,
and Bowery, N.
(1998)
Curr. Opin. Neurobiol.
8,
345-350[CrossRef][Medline]
[Order article via Infotrieve]
6.
Couve, A.,
Filippov, A. K.,
Connelly, C. N.,
Bettler, B.,
Brown, D. A.,
and Moss, S. J.
(1998)
J. Biol. Chem.
273,
26361-26367 7.
Kaupmann, K.,
Malitschek, B.,
Schuler, V.,
Heid, J.,
Froestl, W.,
Beck, P.,
Mosbacher, J.,
Bischoff, S.,
Kulik, A.,
Shigemoto, R.,
Karshin, A.,
and Bettler, B.
(1998)
Nature
396,
683-687[CrossRef][Medline]
[Order article via Infotrieve]
8.
Kuner, R.,
Köhr, G.,
Grünewald, S.,
Eisenhardt, G.,
Bach, A.,
and Kornau, H.-C.
(1999)
Science
283,
74-77 9.
Jones, K. A.,
Borowsky, B.,
Tamm, J. A.,
Craig, D. A.,
Durkin, M. M.,
Dai, M.,
Yao, W.-J.,
Johnson, M.,
Gunwaldsen, C.,
Huang, L.-Y.,
Tang, C.,
Shen, Q.,
Salon, J. A.,
Morse, K.,
Laz, T.,
Smith, K. E.,
Nagarathnam, D.,
Noble, S. A.,
Branchek, T. A.,
and Gerald, C.
(1998)
Nature
396,
674-679[CrossRef][Medline]
[Order article via Infotrieve]
10.
White, J. H.,
Wise, A.,
Main, M. J.,
Green, A.,
Fraser, N. J.,
Disney, G. H.,
Barnes, A. A.,
Emson, P.,
Foord, S. M.,
and Marshall, F. H.
(1998)
Nature
396,
679-682[CrossRef][Medline]
[Order article via Infotrieve]
11.
Ng, G. Y. K.,
Clark, J.,
Coulombe, N.,
Ethier, N.,
Hebert, T. E.,
Sullivan, R.,
Kargman, S.,
Chateauneuf, A.,
Tsukamoto, N.,
McDonald, T.,
Whiting, P.,
Mezey, E.,
Johnson, M. P.,
Liu, Q.,
Kolakowski, L. F., Jr.,
Evans, J. F.,
Bonner, T. I.,
and O'Neill, G. P.
(1999)
J. Biol. Chem.
274,
7607-7610 12.
Kaupmann, K.,
Schuler, V.,
Mosbacher, J.,
Bischoff, S.,
Bittiger, H.,
Heid, J.,
Froestl, W.,
Leonhard, S.,
Pfaff, T.,
Karschin, A.,
and Bettler, B.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14991-14996 13.
Benke, D.,
Mertens, S.,
Trceziak, A.,
Gillessen, D.,
and Mohler, H.
(1991)
J. Biol. Chem.
266,
4478-4483 14.
Carlin, R. K.,
Grab, D. J.,
Cohen, R. S.,
and Siekevitz, P.
(1980)
J. Cell Biol.
86,
831-845 15.
Benke, D.,
Cicin-Sain, A.,
Mertens, S.,
and Mohler, H.
(1991)
J. Recept. Res.
11,
407-424[Medline]
[Order article via Infotrieve]
16.
Mertens, S.,
Benke, D.,
and Mohler, H.
(1993)
J. Biol. Chem.
268,
5965-5973 17.
Wenzel, A.,
Fritschy, J. M.,
Mohler, H.,
and Benke, D.
(1997)
J. Neurochem.
68,
469-478[Medline]
[Order article via Infotrieve]
18.
Wenzel, A.,
Villa, M.,
Mohler, H.,
and Benke, D.
(1996)
J. Neurochem.
66,
1240-1248[Medline]
[Order article via Infotrieve]
19.
Benke, D.,
Wenzel, A.,
Scheurer, L.,
Fritschy, J. M.,
and Mohler, H.
(1995)
J. Recep. Sign. Transd. Res.
15,
393-411
20.
Romano, C.,
Yang, W.-L.,
and O'Malley, K. L.
(1996)
J. Biol. Chem.
271,
28612-28616 21.
Ziff, E. B.
(1997)
Neuron
19,
1163-1174[CrossRef][Medline]
[Order article via Infotrieve]
22.
Lupas, A.
(1996)
Trends Biochem. Sci.
21,
375-382[CrossRef][Medline]
[Order article via Infotrieve]
23.
Bowery, N. G.,
Hudson, A. L.,
and Price, G. W.
(1987)
Neuroscience
20,
365-383[CrossRef][Medline]
[Order article via Infotrieve]
24.
Chu, D. M. C.,
Albin, R. L.,
Young, A. B.,
and Penney, J. B.
(1990)
Neuroscience
34,
341-357[CrossRef][Medline]
[Order article via Infotrieve]
25.
Turgeon, S. M.,
and Albin, R. L.
(1994)
Neuroscience
62,
601-613[CrossRef][Medline]
[Order article via Infotrieve]
26.
Dutar, P.,
and Nicoll, R. A.
(1988)
Neuron
1,
585-598[CrossRef][Medline]
[Order article via Infotrieve]
27.
Stirling, J. M.,
Cross, T. N.,
Robinson, T. N.,
and Green, A. R.
(1989)
Neuropharmacology
28,
699-704[CrossRef][Medline]
[Order article via Infotrieve]
28.
Harrison, N. L.
(1990)
J. Physiol. (Lond.)
422,
433-446 29.
Deisz, R. A.,
Billard, J. M.,
and Zieglgansberger, W.
(1997)
Synapse
25,
62-72[CrossRef][Medline]
[Order article via Infotrieve]
30.
Jordan, B. A.,
and Devi, L. A.
(1999)
Nature
399,
697-700[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
This article has been cited by other articles:
![]() |
T. Grampp, K. Sauter, B. Markovic, and D. Benke {gamma}-Aminobutyric Acid Type B Receptors Are Constitutively Internalized via the Clathrin-dependent Pathway and Targeted to Lysosomes for Degradation J. Biol. Chem., August 17, 2007; 282(33): 24157 - 24165. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Jacobson, B. Bettler, K. Kaupmann, and J. F. Cryan GABAB(1) Receptor Subunit Isoforms Exert a Differential Influence on Baseline but Not GABAB Receptor Agonist-Induced Changes in Mice J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1317 - 1326. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Jacobson, P. H. Kelly, B. Bettler, K. Kaupmann, and J. F. Cryan GABAB(1) Receptor Isoforms Differentially Mediate the Acquisition and Extinction of Aversive Taste Memories. J. Neurosci., August 23, 2006; 26(34): 8800 - 8803. [Abstract] [Full Text] [PDF] |
||||
![]() |